Meina Tang

Meina joined DICE Therapeutics in late Jan 2021 as Vice President of Development Sciences. Prior to DICE, Meina was a Principal Scientist and a therapeutic area lead for autoimmune/inflammatory diseases in the Clinical Pharmacology organization at Genentech, a member of the Roche Group. Prior to joining Genentech in 2009, Meina was Director of PK/PD at PDL Biopharma (later spin off as “Facet Biotech, Corp” and acquired by AbbVie) where she established and managed the PK/PD department after joining the company in 1998.

Over her 22 years of drug development industry experience, Meina was involved as the lead clinical pharmacologist and/or the pharmacology teamleader, in both nonclinical and clinical development of 20+ molecules (including mAbs, F’ab, fusion proteins and small molecule drugs), primarily in autoimmune or inflammatory disease areas, including Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Rheumatoid Arthritis, Lupus, and Asthma.

Meina completed her 3+ years post-doctoral fellowship at Harvard Medical School and holds a Ph.D degree in Physiology from East Tennessee State University.